Workflow
Dencare (Chongqing) Oral Care (001328)
icon
Search documents
登康口腔(001328):24Q4业绩增长提速,电商引领高增
Investment Rating - The report assigns a rating of "Accumulate" for the company [11]. Core Views - The company's performance in Q4 2024 showed significant acceleration in growth, primarily driven by the rapid expansion of e-commerce channels and product structure upgrades, leading to a substantial increase in gross margin. The report maintains a positive outlook on the company's brand momentum and steady high growth [3][11]. Financial Summary - Revenue for 2023 was 1,376 million, projected to grow to 1,560 million in 2024, 1,900 million in 2025, 2,294 million in 2026, and 2,756 million in 2027, reflecting growth rates of 4.8%, 13.4%, 21.8%, 20.7%, and 20.2% respectively [5]. - Net profit attributable to the parent company was 141 million in 2023, expected to rise to 161 million in 2024, 201 million in 2025, 251 million in 2026, and 304 million in 2027, with growth rates of 5.0%, 14.1%, 24.8%, 24.7%, and 21.2% respectively [5]. - The earnings per share (EPS) is projected to increase from 0.82 in 2023 to 0.94 in 2024, 1.17 in 2025, 1.46 in 2026, and 1.77 in 2027 [5]. Revenue Breakdown - In 2024, the company achieved revenues of 10.32 million from distribution, 0.41 million from direct supply, and 4.81 million from e-commerce, with year-on-year growth rates of 4%, -24%, and 52% respectively. The e-commerce segment's contribution increased to 31% [11]. - The adult toothpaste segment was the main growth driver, with revenues of 12.47 million, reflecting a 16% increase. The oral medical and beauty care products also showed strong growth, with a 35% increase in revenue [11]. Margin Analysis - The gross margin for 2024 is projected at 49.37%, an increase of 5.26 percentage points year-on-year, primarily due to the high-margin products in the e-commerce channel. The gross margin is expected to further improve to 55.51% in Q1 2025 [11].
登康口腔(001328):2024A、2025Q1:电商提速+结构优化,商业模式渐入佳境
Changjiang Securities· 2025-04-24 04:43
Investment Rating - The investment rating for the company is "Buy" and is maintained [10] Core Views - The company is expected to achieve revenue, net profit attributable to the parent, and net profit excluding non-recurring items of 1.56 billion, 161 million, and 135 million yuan in 2024, representing year-on-year growth of 13%, 14%, and 27% respectively [2][6] - The fourth quarter of 2024 is projected to see significant growth, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items increasing by 39%, 29%, and 119% respectively [2][6] - For the first quarter of 2025, the company anticipates revenue of 430 million yuan, net profit attributable to the parent of 43 million yuan, and net profit excluding non-recurring items of 36 million yuan, reflecting year-on-year growth of 19%, 16%, and 27% respectively [2][6] Summary by Sections Revenue Growth - The company is leveraging e-commerce channels to enhance brand exposure and reshape market dynamics, with significant improvements in team building, advertising strategies, and product launches [8] - In Q1, the company's cold acid spirit product on Douyin saw a GMV increase of over 300%, while Tmall's GMV grew by 77% [8] Product Pricing and Structure - The company is focusing on high-functionality and marketing characteristics of toothpaste, with the "7-day repair" series rapidly increasing its market share, accounting for 70%-80% of sales on Douyin by the end of 2024 [8] - The average price per hundred grams reached 26.6 yuan, surpassing its mainstream price level of 10-13 yuan and exceeding the popular Yunnan Baiyao series [8] Financial Performance - The company expects to see a dual increase in gross sales and slight profit growth, with gross margin, sales expense ratio, and net profit margin showing improvements in 2024 and Q1 2025 [14] - The company is projected to achieve net profits of 203 million, 260 million, and 328 million yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 36, 28, and 22 times [14]
美容护理板块持续拉升,百亚股份冲击涨停
news flash· 2025-04-24 02:06
暗盘资金正涌入这些股票,点击速看>>> 美容护理板块持续拉升,百亚股份(003006)冲击涨停,登康口腔(001328)涨超7%,丸美生物 (603983)涨超6%,拉芳家化(603630)、豪悦护理(605009)涨幅居前。 ...
登康口腔:电商助力高毛利产品成长-20250423
Tianfeng Securities· 2025-04-23 10:23
Investment Rating - The investment rating for the company is "Accumulate" with a target price not specified [5] Core Viewpoints - The company is experiencing growth driven by e-commerce channels, with a significant increase in high-margin product sales [2] - The company aims to expand its business into the oral health sector, focusing on oral care, medical, and beauty services [4] - The core brand "Ling Suan Ling" has established itself as a leader in the sensitive toothpaste segment, with a market share increase projected [3] Summary by Sections Financial Performance - In Q1 2025, the company reported revenue of 430 million, a 19% increase year-on-year, and a net profit of 43 million, up 15.6% [1] - For 2024, the projected revenue is 1.56 billion, a 13.4% increase, with a net profit of 161 million, reflecting a 14% growth [1] Sales Channels - Revenue breakdown for 2024 shows distribution revenue at 1.03 billion (up 3.7%), direct supply at 40 million (down 24%), and e-commerce at 480 million (up 52%) [2] - The company is leveraging refined operations and deep integration of platform resources to enhance user engagement and sales [2] Product Performance - Adult toothpaste revenue is projected at 1.25 billion (up 16%), while children's toothpaste is expected to decline to 30 million (down 5%) [2] - The company is expanding its product line to include electric oral care products, contributing to a 35% increase in revenue from oral medical and beauty care products [4] Market Position - The company ranks third in the toothpaste market and second among domestic brands, with its core brand "Ling Suan Ling" holding a 64.7% market share in the sensitive segment by 2024 [3] - The toothbrush segment is also performing well, with significant market share growth, particularly in the children's category [3] Future Outlook - The company plans to continue developing its oral health ecosystem, focusing on high-end products and expanding into new market segments [4][8] - Revenue forecasts for 2025 to 2027 indicate a steady growth trajectory, with net profits expected to reach 196.89 million in 2025, 248.73 million in 2026, and 314.85 million in 2027 [10][11]
登康口腔:产品升级与渠道扩张齐驱,业绩持续稳步提升-20250423
Guoxin Securities· 2025-04-23 08:25
Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][20] Core Views - The company is expected to achieve revenue of 1.56 billion with a year-on-year growth of 13.4% in 2024, and a net profit of 161 million, reflecting a year-on-year increase of 14.07% [1][8] - The adult basic oral care segment remains the primary revenue source, contributing 1.407 billion, which accounts for 90.22% of total revenue [2][9] - The company is focusing on product upgrades and channel expansion, particularly through online sales, which have shown significant growth [1][4][10] Revenue and Profitability - In Q4 2024, the company achieved a revenue growth of 39.12% and a net profit growth of 28.58% [1][8] - The gross margin for 2024 is projected to be 49.37%, an increase of 5.26 percentage points year-on-year [13][18] - The company plans to distribute a cash dividend of 7.5 yuan per 10 shares [1][8] Segment Performance - The adult basic oral care segment's revenue grew by 14.48% year-on-year, while the children's segment saw a decline of 1.90% [2][9] - The e-commerce channel experienced a robust growth of 51.99%, increasing its revenue share to 30.81% [2][9] Future Outlook - The company is expected to maintain strong growth in Q1 2025, with a revenue increase of 19.36% and a net profit increase of 15.64% [3][10] - The forecast for net profit is 224 million in 2025, 286 million in 2026, and 344 million in 2027, with corresponding P/E ratios of 33, 26, and 22 [4][20] Financial Metrics - The company’s operating cash flow for 2024 is projected to be 181 million, reflecting a year-on-year increase of 20.09% [18][23] - The net profit margin for 2024 is expected to be 10.33%, with a slight increase from the previous year [13][18]
登康口腔(001328):电商助力高毛利产品成长
Tianfeng Securities· 2025-04-23 07:42
Investment Rating - The investment rating for the company is "Accumulate" with a target price not specified [5] Core Views - The company reported a revenue of 430 million with a year-on-year growth of 19% in Q1 2025, and a net profit attributable to the parent company of 43 million, up 15.6% year-on-year [1] - The revenue forecast for 2024 is 1.56 billion, representing a 13.4% increase, with a net profit of 161 million, up 14% year-on-year [1] - The e-commerce channel is driving growth, with e-commerce revenue expected to reach 480 million in 2024, a 52% increase [2] - The company is focusing on high-margin products and leveraging its brand strategy to enhance profitability [2] Revenue Breakdown - For 2024, revenue from distribution is projected at 1.03 billion, a 3.7% increase, while direct supply revenue is expected to decline by 24% to 40 million [2] - The adult toothpaste segment is expected to generate 1.25 billion, up 16%, while children's toothpaste is projected to decline by 5% to 30 million [2] Market Position - The company ranks third in the toothpaste market and second among domestic brands, with its core brand "Cold Acid Spirit" holding a market share of 64.7% in the sensitive toothpaste segment by 2024 [3] - The toothbrush segment is also performing well, with the brand ranking second in retail market share [3] Product Expansion - The company is expanding its product offerings into oral medical and beauty care products, with a revenue increase of 35.5% in this segment for 2024 [4] - Future plans include developing electric oral care products and enhancing its presence in the oral health ecosystem [4][8] Financial Projections - The company expects to achieve a net profit of 196.89 million in 2025, with an EPS of 1.14 yuan [9] - Revenue is projected to grow to 1.89 billion in 2025, reflecting a growth rate of 21.1% [10] - The gross margin is expected to improve to 50% by 2025 [11]
登康口腔(001328):产品升级与渠道扩张齐驱,业绩持续稳步提升
Guoxin Securities· 2025-04-23 06:05
Investment Rating - The investment rating for the company is "Outperform the Market" [6][20][25] Core Views - The company is expected to achieve revenue of 1.56 billion in 2024, representing a year-over-year increase of 13.4%, with a net profit of 161 million, up 14.07% year-over-year [1][8] - The adult basic oral care segment remains the primary revenue source, generating 1.407 billion in 2024, accounting for 90.22% of total revenue [2][9] - The company is focusing on product upgrades and channel expansion, particularly through online sales, which have shown significant growth [1][4][20] Revenue and Profitability - In Q4 2024, the company achieved a revenue growth of 39.12% and a net profit growth of 28.58% [1][8] - The gross margin for 2024 is projected to be 49.37%, an increase of 5.26 percentage points year-over-year [13][18] - The company plans to distribute a cash dividend of 7.5 per 10 shares (tax included) [1][8] Segment Performance - The adult basic oral care segment's revenue grew by 14.48% year-over-year, while the children's segment saw a decline of 1.90% [2][9] - The e-commerce channel is experiencing robust growth, with a revenue increase of 51.99% in 2024, raising its contribution to 30.81% of total revenue [2][9] Future Outlook - The company is expected to maintain healthy growth in Q1 2025, with projected revenue of 430 million, a year-over-year increase of 19.36% [3][10] - The net profit for 2025 is forecasted to reach 224 million, reflecting a growth rate of 39.1% [5][20] - The company aims to enhance its market position through diversified expansion and brand strengthening via social media channels [4][20]
登康口腔:大单品带动线上放量,毛销差优化-20250422
China Post Securities· 2025-04-22 14:23
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][14]. Core Insights - The company reported a revenue of 1.56 billion yuan for 2024, representing a year-over-year growth of 13.4%, with a net profit of 161 million yuan, up 14.1% year-over-year. The fourth quarter of 2024 saw a significant revenue increase of 39% year-over-year [4][5]. - The company's online sales are driven by a major product, with e-commerce revenue growing by 52% year-over-year, indicating strong growth potential for 2025 [5]. - The gross profit margin for 2024 was 49.4%, an increase of 5.3 percentage points year-over-year, reflecting improved profitability [6]. - The company is expected to continue expanding its market share in oral care and beauty, with projected net profits of 200 million yuan, 252 million yuan, and 317 million yuan for 2025, 2026, and 2027 respectively [7][10]. Financial Summary - The latest closing price of the company's stock is 44.68 yuan, with a total market capitalization of 7.7 billion yuan [3]. - The company’s earnings per share (EPS) for 2024 is projected at 0.94 yuan, with a price-to-earnings (P/E) ratio of 47.73 [10][13]. - The company’s revenue is expected to grow to 1.89 billion yuan in 2025, with a growth rate of 21.3% [10][11].
登康口腔(001328):大单品带动线上放量,毛销差优化
China Post Securities· 2025-04-22 13:04
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][14]. Core Insights - The company reported a revenue of 1.56 billion yuan for 2024, representing a year-over-year growth of 13.4%, with a net profit of 161 million yuan, up 14.1% year-over-year [4]. - The fourth quarter of 2024 saw a significant revenue increase of 39% year-over-year, reaching 507 million yuan, with a net profit of 43 million yuan, up 28.6% year-over-year [4]. - The first quarter of 2025 continued this trend with a revenue of 430 million yuan, a 19.4% increase year-over-year, and a net profit of 43 million yuan, up 15.6% year-over-year [4]. Revenue Breakdown - In 2024, the company's revenue from different channels was as follows: distribution model 1.03 billion yuan (+3.7% YoY), direct supply model 40 million yuan (-24.0% YoY), and e-commerce model 480 million yuan (+52.0% YoY) [5]. - The revenue from various product categories in 2024 included: adult toothpaste 1.25 billion yuan (+16.1% YoY), adult toothbrush 160 million yuan (+3.3% YoY), children's toothpaste 70 million yuan (-0.5% YoY), children's toothbrush 30 million yuan (-5.1% YoY), electric toothbrush 10 million yuan (-14.3% YoY), and oral medical and beauty care products 40 million yuan (+35.5% YoY) [5]. Profitability Analysis - The company's gross margin for 2024 was 49.4%, an increase of 5.3 percentage points year-over-year, while the net profit margin was 10.3%, showing a slight improvement [6]. - In the first quarter of 2025, the gross margin rose to 55.5%, a year-over-year increase of 7.1 percentage points, while the net profit margin slightly decreased to 10.0% due to fluctuations in fair value changes [6]. Financial Forecast and Investment Recommendations - The company is expected to see steady growth in its core oral care market, with projected net profits of 200 million yuan, 250 million yuan, and 320 million yuan for 2025, 2026, and 2027 respectively, corresponding to price-to-earnings ratios of 39x, 31x, and 24x [7]. - The report highlights the company's strong cash flow and high dividend payout ratio, which are expected to enhance its valuation premium [7]. Financial Metrics - The projected revenue for the company is expected to grow from 1.56 billion yuan in 2024 to 2.78 billion yuan in 2027, with a compound annual growth rate of approximately 20.87% [10]. - The earnings per share (EPS) is forecasted to increase from 0.94 yuan in 2024 to 1.84 yuan in 2027 [10].
登康口腔(001328):2024A、2025Q1业绩点评报告:电商为核心驱动,产品结构优化助毛利率提升
ZHESHANG SECURITIES· 2025-04-22 12:47
Investment Rating - The investment rating for the company is "Add" (maintained) [6] Core Views - The company achieved a revenue of 1.56 billion yuan in 2024, representing a year-on-year increase of 13.4%, and a net profit of 160 million yuan, up 14.1% year-on-year [1] - The adult toothpaste segment showed excellent growth, with revenue increasing by 16.1%, while the e-commerce channel remains the core driver of the company's growth [2] - The optimization of product structure has significantly boosted the gross margin, which reached 49.37% in 2024, up 5.3 percentage points year-on-year [3] Financial Performance - In 2024, the company reported a net cash flow from operating activities of 181 million yuan, a year-on-year increase of 20.1% [4] - The company's gross margin for adult toothpaste was 50.47%, reflecting a 5.5 percentage point increase year-on-year [3] - The company’s net profit margin for 2024 was 10.33%, a slight increase of 0.06 percentage points year-on-year [3] Market Position - The company has maintained a steady increase in market share, ranking third in the offline retail channel for toothpaste products, and second among domestic brands [5] - The "Cold Acid Spirit" brand has seen its market share in the sensitive toothpaste segment increase from 61.74% in 2022 to 64.72% in 2024 [5] Earnings Forecast - The company is expected to achieve revenues of 1.87 billion yuan, 2.27 billion yuan, and 2.80 billion yuan in 2025, 2026, and 2027, respectively, with year-on-year growth rates of 19.65%, 21.73%, and 23.21% [10] - The forecasted net profit for 2025 is 196 million yuan, representing a year-on-year growth of 21.75% [10]